Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Kids living in poverty lack sleep, physical activity

30 Oct 2019

Toddlers from families living in poverty are likely to not meet guidelines for physical activity and sleep, a recent study has found.

The study included 101 toddlers (mean age, 20.2±5.5 months; 61 percent male) from low-income families. Participants were made to wear ankle accelerometers for 24 hours over 3–7 consecutive days. Parent reports on wake/sleep patterns of their children were used to verify daytime napping data.

Toddlers slept for an average of 499.8 minutes per night, corresponding to approximately 8 hours of sleep. The average bed and wake times were 9:36 PM and 8:10 AM. Sleep efficiency was at 80 percent, and an average of 1.8 naps were taken daily, each lasting a mean of 67.2 minutes. Overall, 44 percent of the 24-hour day was spent sleeping.

In terms of activity, participants spent 172 minutes in sedentary behaviour, 54.5 minutes in moderate-to-vigorous physical activity (MVPA) and 579.8 minutes in light activity.

Only 32 percent of the participating toddlers met the recommendation of 11–14 hours of sleep within 24 hours, while only 26 percent met bedtime guidelines. Thirty-eight percent satisfied the preschool physical activity guideline of ≥60 minutes of MVPA.

Children living above the poverty line were significantly more likely to meet a greater number of sleep and activity guidelines than their counterparts (r, –0.229; p=0.02). Similarly, those who were not living in poverty were significantly more likely to fulfil the ≥60-minute MVPA daily requirement (odds ratio, 3.703, 95 percent CI, 1.455–9.428; p<0.05).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.